Announcement of the Implementation Status of the Remediation Plan for Excessive Intercompany Loans by Subsidiary
Key facts
- Announcement of the Implementation Status of the Remediation Plan for Excessive Intercompany Loans by Subsidiary
- Mei-Shih announced the completion of a remediation plan regarding excessive fund lending by its subsidiary, Alvogen Pharma US Inc. The company has strengthened internal controls and governance procedures in response to regulatory requirements.
- Source: PR Times
- Date: June 27, 2026
Direct answer
Mei-Shih announced the completion of a remediation plan regarding excessive fund lending by its subsidiary, Alvogen Pharma US Inc. The company has strengthened internal controls and governance procedures in response to regulatory requirements.
- Citation
- Announcement of the Implementation Status of the Remediation Plan for Excessive Intercompany Loans by Subsidiary (June 27, 2026), PR Times
- Source
- PR Times
- Date
- June 27, 2026
Mei-Shih announced the completion of a remediation plan regarding excessive fund lending by its subsidiary, Alvogen Pharma US Inc. The company has strengthened internal controls and governance procedures in response to regulatory requirements.
📋 Article Processing Timeline
- 📰 Published: June 27, 2026 at 09:00
- 🔍 Collected: June 27, 2026 at 23:58 (14h 58m after Published)
- 🤖 AI Analyzed: June 28, 2026 at 00:01 (2 min after Collected)
Date of Announcement: June 26, 115
Time of Announcement: 19:44:16
Company Code: 1795
Company Name: Mei-Shih
Subject: Announcement on Behalf of Subsidiary Regarding the Implementation Status of the Remediation Plan for Excessive Fund Lending to Others
Applicable Clause: Clause 51
Date of Event: June 26, 115
Details:
1. Date of Event: June 26, 115
2. Company Name: Alvogen Pharma US Inc.
3. Relationship with Company (Please enter 'Company' or 'Subsidiary'): Subsidiary
4. Cross-shareholding Ratio: Subsidiary fully owned (100%) by the Company
5. Reason for Occurrence: In accordance with the Financial Supervisory Commission's letter No. 1150335969, the Company is required to complete a remediation plan for its subsidiary's excessive fund lending by June 30, 115, and the Board of Directors must oversee the implementation.
6. Remedial Measures:
(1) The U.S. subsidiary established an operational procedure for fund lending to others by the end of March 115, in compliance with the 'Regulations on Fund Lending and Endorsement Guarantees for Publicly Issued Companies'.
(2) The Company revised its fund lending and endorsement guarantee procedures, approved during the 115 Annual General Meeting of Shareholders.
(3) The Company reported the completion of remedial measures to the Audit and Risk Management Committee on June 25, 115, and to the Board of Directors on June 26, 115.
7. Other Matters to be Disclosed (If the entity involved in the event or resolution is a publicly issued company or above, this material information also qualifies as a matter under Article 7, Paragraph 9, Item 9 of the Enforcement Rules of the Securities and Exchange Act that significantly affects shareholders' rights or securities prices): None
Time of Announcement: 19:44:16
Company Code: 1795
Company Name: Mei-Shih
Subject: Announcement on Behalf of Subsidiary Regarding the Implementation Status of the Remediation Plan for Excessive Fund Lending to Others
Applicable Clause: Clause 51
Date of Event: June 26, 115
Details:
1. Date of Event: June 26, 115
2. Company Name: Alvogen Pharma US Inc.
3. Relationship with Company (Please enter 'Company' or 'Subsidiary'): Subsidiary
4. Cross-shareholding Ratio: Subsidiary fully owned (100%) by the Company
5. Reason for Occurrence: In accordance with the Financial Supervisory Commission's letter No. 1150335969, the Company is required to complete a remediation plan for its subsidiary's excessive fund lending by June 30, 115, and the Board of Directors must oversee the implementation.
6. Remedial Measures:
(1) The U.S. subsidiary established an operational procedure for fund lending to others by the end of March 115, in compliance with the 'Regulations on Fund Lending and Endorsement Guarantees for Publicly Issued Companies'.
(2) The Company revised its fund lending and endorsement guarantee procedures, approved during the 115 Annual General Meeting of Shareholders.
(3) The Company reported the completion of remedial measures to the Audit and Risk Management Committee on June 25, 115, and to the Board of Directors on June 26, 115.
7. Other Matters to be Disclosed (If the entity involved in the event or resolution is a publicly issued company or above, this material information also qualifies as a matter under Article 7, Paragraph 9, Item 9 of the Enforcement Rules of the Securities and Exchange Act that significantly affects shareholders' rights or securities prices): None
FAQ
Why did Mei-Shih's subsidiary face a fund lending issue?
The subsidiary exceeded lending limits, prompting regulatory correction orders from Taiwan's FSC.
What does the remediation plan include?
It includes procedure establishment, policy revisions, and reporting to audit and board committees.
What impact does this have on shareholders?
No major financial impact, but it raises governance transparency concerns.
When must the remediation be completed?
By June 30, 115, as directed by the Financial Supervisory Commission.
What is the ownership status of Alvogen Pharma US Inc.?
It is a 100%-owned subsidiary of Mei-Shih and consolidated in its financials.